Sort   by:  
 Page size 
UnknownFulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Not available
S-EPMC4737861 | biostudies-literature
UnknownPhase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
Not available
S-EPMC5012690 | biostudies-literature
UnknownTreatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Not available
S-EPMC4289722 | biostudies-literature
UnknownKi67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Not available
S-EPMC5455353 | biostudies-literature
ProteomicsKinase Inhibitor Pulldown Assay (KiP) for Clinical Proteomics
Protein kinases are frequently dysregulated and/or mutated in cancer and represent essential targets for therapy. Accurate quantification is essential, but current approaches are inadequate. For breast cancer treatment for example, the identification and quantification of the protein kinase ERBB2 is...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD044655 | Pride
Human Breast Cancer Kinase 
ProteomicsKinase Inhibitor Pulldown Assay (KiP) for Clinical Proteomics (SureQuant)
Protein kinases are frequently dysregulated and/or mutated in cancer and represent essential targets for therapy. Accurate quantification is essential, but current approaches are inadequate. For breast cancer treatment for example, the identification and quantification of the protein kinase ERBB2 is...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD046169 | Pride
Breast cancer Is-prm Surequant Kip 
TranscriptomicsGene expression during SMC cord morphogenesis
SMCs must undergo specialzed patterning during blood vessel stabilization. We used microarray analysis to identify differentially expressed genes as smooth muscle cells were induced to assemble into a network of elongated cords. Two time points (Day 0 and Day 8) and three biological replicates for e...
ORGANISM(S): Homo sapiens 
2011-04-17 | E-GEOD-21363 | biostudies-arrayexpress
ProteomicsDAPK3 modulates migration and invasion of triple negative breast cancers
A mass spectrometry (MS)-based kinase inhibitor pulldown assay (KIPA) was applied to analyze 16 patient-derived xenografts (PDXs) leading to the discovery that Death-Associated Protein Kinase 3 (DAPK3) is significantly and specifically overexpressed in triple negative breast cancer (TNBC). Validatio...
ORGANISM(S): Homo sapiens (Human) 
2025-05-06 | PXD049187 | Pride
Luzp1 Emt Breast cancer Cancer Dapk3 Pdx 
UnknownExemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Not available
S-EPMC3612593 | biostudies-literature
GenomicsA Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.

Source of Patients
The source of the patients for this genome-wide case control study was MA.27, which was conducted as a multi-cooperative group effort under the auspices of the NCI Breast Cancer Intergroup of North America. The NCIC Clinical Trials Group (CTG) serves as the co...

phs000210.v1.p1 | EGA
Sort   by:  
 Page size